25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALGS (Aligos) Stock Analysis
Buy, Hold or Sell?

Let's analyze Aligos together

I guess you are interested in Aligos Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Aligos’s Financial Insights
  • 📈 Technical Analysis (TA) – Aligos’s Price Targets

I'm going to help you getting a better view of Aligos Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Aligos Therapeutics Inc

I send you an email if I find something interesting about Aligos Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Aligos (30 sec.)










1.2. What can you expect buying and holding a share of Aligos? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
9.1%

What is your share worth?

Current worth
$13.37
Expected worth in 1 year
$15.49
How sure are you?
31.8%

+ What do you gain per year?

Total Gains per Share
$2.12
Return On Investment
24.1%

For what price can you sell your share?

Current Price per Share
$8.79
Expected price per share
$6.45 - $28.10
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Aligos (5 min.)




Live pricePrice per Share (EOD)
$8.79
Intrinsic Value Per Share
$-141.73 - $-167.69
Total Value Per Share
$-128.36 - $-154.32

2.2. Growth of Aligos (5 min.)




Is Aligos growing?

Current yearPrevious yearGrowGrow %
How rich?$116.4m$69m-$17.8m-34.9%

How much money is Aligos making?

Current yearPrevious yearGrowGrow %
Making money-$13.3m-$24.8m$11.5m87.0%
Net Profit Margin-61.6%-1,351.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Aligos (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#320 / 872

Most Revenue
#467 / 872

Most Profit
#571 / 872

Most Efficient
#487 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Aligos?

Welcome investor! Aligos's management wants to use your money to grow the business. In return you get a share of Aligos.

First you should know what it really means to hold a share of Aligos. And how you can make/lose money.

Speculation

The Price per Share of Aligos is $8.79. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Aligos.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Aligos, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $13.37. Based on the TTM, the Book Value Change Per Share is $0.53 per quarter. Based on the YOY, the Book Value Change Per Share is $2.32 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Aligos.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps4.9556.3%-2.56-29.1%-2.40-27.3%-1.82-20.7%-1.44-16.4%-1.39-15.8%
Usd Book Value Change Per Share17.98204.6%0.536.0%2.3226.4%0.819.3%0.829.3%0.616.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.070.7%0.060.7%
Usd Total Gains Per Share17.98204.6%0.536.0%2.3226.4%0.829.3%0.8810.0%0.677.6%
Usd Price Per Share8.25-14.28-0.84-5.38-8.25-7.50-
Price to Earnings Ratio0.42--0.24--0.28--0.35--1.68--1.53-
Price-to-Total Gains Ratio0.46--1.08--1.13--1.60--2.87--2.87-
Price to Book Ratio0.62--1.73-0.34--0.33-0.76-0.69-
Price-to-Total Gains Ratio0.46--1.08--1.13--1.60--2.87--2.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.79
Number of shares113
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.07
Usd Book Value Change Per Share0.530.82
Usd Total Gains Per Share0.530.88
Gains per Quarter (113 shares)59.8599.68
Gains per Year (113 shares)239.42398.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1023922930369389
2047946859738788
307187078911071187
4095894611914761586
501197118514918451985
601437142417822142384
701676166320825832783
801915190223829523182
902155214126733213581
1002394238029736903980

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%2.010.00.016.7%2.018.00.010.0%2.020.00.09.1%2.020.00.09.1%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%7.014.01.031.8%7.014.01.031.8%
Dividend per Share0.00.04.00.0%1.00.011.08.3%2.00.018.010.0%2.00.020.09.1%2.00.020.09.1%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%7.014.01.031.8%7.014.01.031.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Aligos Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--17.9820.530+3295%2.319+675%0.814+2108%0.816+2102%0.608+2859%
Book Value Per Share--13.3707.348+82%5.347+150%5.104+162%4.644+188%3.953+238%
Current Ratio--7.5584.613+64%4.735+60%4.628+63%5.422+39%5.673+33%
Debt To Asset Ratio--0.2270.614-63%0.410-45%0.433-48%0.453-50%0.543-58%
Debt To Equity Ratio--0.2940.419-30%0.725-59%0.509-42%0.392-25%0.439-33%
Dividend Per Share----0%0.003-100%0.001-100%0.066-100%0.060-100%
Enterprise Value--175461967.250132351324.588+33%75154660.570+133%114218807.930+54%338458261.825-48%338458261.825-48%
Eps--4.947-2.562+152%-2.403+149%-1.817+137%-1.439+129%-1.387+128%
Ev To Ebitda Ratio---2.342-1.661-29%-0.908-61%-1.416-40%-3.054+30%-3.054+30%
Ev To Sales Ratio--141.04763.655+122%7.354+1818%26.876+425%73.591+92%73.591+92%
Free Cash Flow Per Share---2.406-3.054+27%-1.716-29%-1.749-27%-1.316-45%-1.273-47%
Free Cash Flow To Equity Per Share--9.276-0.117+101%0.020+46025%-0.191+102%0.018+52144%0.116+7913%
Gross Profit Margin--1.0000.970+3%1.007-1%0.992+1%0.995+0%0.996+0%
Intrinsic Value_10Y_max---167.694----------
Intrinsic Value_10Y_min---141.729----------
Intrinsic Value_1Y_max---8.429----------
Intrinsic Value_1Y_min---8.274----------
Intrinsic Value_3Y_max---31.708----------
Intrinsic Value_3Y_min---30.142----------
Intrinsic Value_5Y_max---62.683----------
Intrinsic Value_5Y_min---57.631----------
Market Cap46717092.000-54%71854967.25094577574.588-24%22019410.570+226%53614807.930+34%219156635.642-67%199233305.129-64%
Net Profit Margin--138.547-0.616+100%-13.515+110%-6.756+105%-14.106+110%-12.824+109%
Operating Margin---61.875-33.975-45%-10.360-83%-16.893-73%-20.065-68%-18.241-71%
Operating Ratio--62.87535.098+79%11.432+450%18.040+249%28.038+124%25.489+147%
Pb Ratio0.657+6%0.617-1.727+380%0.343+80%-0.328+153%0.763-19%0.694-11%
Pe Ratio0.444+6%0.417-0.239+157%-0.280+167%-0.353+185%-1.680+503%-1.528+466%
Price Per Share8.790+6%8.25014.275-42%0.841+882%5.383+53%8.245+0%7.496+10%
Price To Free Cash Flow Ratio-0.913-7%-0.857-1.238+44%-0.330-62%-0.707-17%-2.286+167%-2.078+142%
Price To Total Gains Ratio0.489+6%0.459-1.078+335%-1.131+346%-1.601+449%-2.869+725%-2.869+725%
Quick Ratio--10.6596.443+65%5.707+87%6.052+76%6.663+60%7.647+39%
Return On Assets--0.286-0.264+192%-0.210+174%-0.205+172%-0.190+167%-0.185+165%
Return On Equity--0.3700.015+2332%-0.371+200%-0.184+150%-0.172+146%-0.164+144%
Total Gains Per Share--17.9820.530+3295%2.322+675%0.815+2105%0.882+1938%0.667+2594%
Usd Book Value--116445000.00051199250.000+127%69083000.000+69%77397750.000+50%102641700.000+13%87411454.545+33%
Usd Book Value Change Per Share--17.9820.530+3295%2.319+675%0.814+2108%0.816+2102%0.608+2859%
Usd Book Value Per Share--13.3707.348+82%5.347+150%5.104+162%4.644+188%3.953+238%
Usd Dividend Per Share----0%0.003-100%0.001-100%0.066-100%0.060-100%
Usd Enterprise Value--175461967.250132351324.588+33%75154660.570+133%114218807.930+54%338458261.825-48%338458261.825-48%
Usd Eps--4.947-2.562+152%-2.403+149%-1.817+137%-1.439+129%-1.387+128%
Usd Free Cash Flow---20952000.000-19752500.000-6%-19861000.000-5%-20019250.000-4%-21632600.000+3%-21354545.455+2%
Usd Free Cash Flow Per Share---2.406-3.054+27%-1.716-29%-1.749-27%-1.316-45%-1.273-47%
Usd Free Cash Flow To Equity Per Share--9.276-0.117+101%0.020+46025%-0.191+102%0.018+52144%0.116+7913%
Usd Market Cap46717092.000-54%71854967.25094577574.588-24%22019410.570+226%53614807.930+34%219156635.642-67%199233305.129-64%
Usd Price Per Share8.790+6%8.25014.275-42%0.841+882%5.383+53%8.245+0%7.496+10%
Usd Profit--43088000.000-13315000.000+131%-24896750.000+158%-19686083.333+146%-24434600.000+157%-23950227.273+156%
Usd Revenue--311000.000817500.000-62%3448000.000-91%2593416.667-88%1476450.000-79%1342227.273-77%
Usd Total Gains Per Share--17.9820.530+3295%2.322+675%0.815+2105%0.882+1938%0.667+2594%
 EOD+3 -5MRQTTM+27 -11YOY+27 -133Y+28 -125Y+26 -1410Y+26 -14

3.3 Fundamental Score

Let's check the fundamental score of Aligos Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-150.444
Price to Book Ratio (EOD)Between0-10.657
Net Profit Margin (MRQ)Greater than0138.547
Operating Margin (MRQ)Greater than0-61.875
Quick Ratio (MRQ)Greater than110.659
Current Ratio (MRQ)Greater than17.558
Debt to Asset Ratio (MRQ)Less than10.227
Debt to Equity Ratio (MRQ)Less than10.294
Return on Equity (MRQ)Greater than0.150.370
Return on Assets (MRQ)Greater than0.050.286
Total9/10 (90.0%)

3.4 Technical Score

Let's check the technical score of Aligos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose8.640
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Aligos Therapeutics Inc

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2025-07-10 20:17:04.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Aligos earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • A Net Profit Margin of 13,854.7% means that $138.55 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Aligos Therapeutics Inc:

  • The MRQ is 13,854.7%. The company is making a huge profit. +2
  • The TTM is -61.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ13,854.7%TTM-61.6%+13,916.3%
TTM-61.6%YOY-1,351.5%+1,289.9%
TTM-61.6%5Y-1,410.6%+1,349.0%
5Y-1,410.6%10Y-1,282.4%-128.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13,854.7%-92.7%+13,947.4%
TTM-61.6%-140.3%+78.7%
YOY-1,351.5%-196.4%-1,155.1%
3Y-675.6%-248.5%-427.1%
5Y-1,410.6%-343.4%-1,067.2%
10Y-1,282.4%-496.2%-786.2%
4.3.1.2. Return on Assets

Shows how efficient Aligos is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • 28.6% Return on Assets means that Aligos generated $0.29 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Aligos Therapeutics Inc:

  • The MRQ is 28.6%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is -26.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ28.6%TTM-26.4%+55.0%
TTM-26.4%YOY-21.0%-5.4%
TTM-26.4%5Y-19.0%-7.4%
5Y-19.0%10Y-18.5%-0.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ28.6%-11.6%+40.2%
TTM-26.4%-11.6%-14.8%
YOY-21.0%-11.4%-9.6%
3Y-20.5%-11.8%-8.7%
5Y-19.0%-12.0%-7.0%
10Y-18.5%-13.7%-4.8%
4.3.1.3. Return on Equity

Shows how efficient Aligos is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • 37.0% Return on Equity means Aligos generated $0.37 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Aligos Therapeutics Inc:

  • The MRQ is 37.0%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 1.5%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ37.0%TTM1.5%+35.5%
TTM1.5%YOY-37.1%+38.6%
TTM1.5%5Y-17.2%+18.7%
5Y-17.2%10Y-16.4%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ37.0%-13.6%+50.6%
TTM1.5%-15.0%+16.5%
YOY-37.1%-14.5%-22.6%
3Y-18.4%-16.9%-1.5%
5Y-17.2%-17.5%+0.3%
10Y-16.4%-19.9%+3.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Aligos Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Aligos is operating .

  • Measures how much profit Aligos makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • An Operating Margin of -6,187.5% means the company generated $-61.87  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Aligos Therapeutics Inc:

  • The MRQ is -6,187.5%. The company is operating very inefficient. -2
  • The TTM is -3,397.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-6,187.5%TTM-3,397.5%-2,790.0%
TTM-3,397.5%YOY-1,036.0%-2,361.5%
TTM-3,397.5%5Y-2,006.5%-1,391.0%
5Y-2,006.5%10Y-1,824.1%-182.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6,187.5%-229.2%-5,958.3%
TTM-3,397.5%-249.0%-3,148.5%
YOY-1,036.0%-208.5%-827.5%
3Y-1,689.3%-223.8%-1,465.5%
5Y-2,006.5%-346.1%-1,660.4%
10Y-1,824.1%-475.5%-1,348.6%
4.3.2.2. Operating Ratio

Measures how efficient Aligos is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 62.87 means that the operating costs are $62.87 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 62.875. The company is inefficient in keeping operating costs low. -1
  • The TTM is 35.098. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ62.875TTM35.098+27.777
TTM35.098YOY11.432+23.666
TTM35.0985Y28.038+7.060
5Y28.03810Y25.489+2.549
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ62.8752.110+60.765
TTM35.0982.684+32.414
YOY11.4323.096+8.336
3Y18.0403.652+14.388
5Y28.0384.745+23.293
10Y25.4896.614+18.875
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Aligos Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Aligos is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.56 means the company has $7.56 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 7.558. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.613. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.558TTM4.613+2.945
TTM4.613YOY4.735-0.122
TTM4.6135Y5.422-0.809
5Y5.42210Y5.673-0.251
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.5583.661+3.897
TTM4.6133.846+0.767
YOY4.7354.140+0.595
3Y4.6284.688-0.060
5Y5.4225.746-0.324
10Y5.6736.147-0.474
4.4.3.2. Quick Ratio

Measures if Aligos is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • A Quick Ratio of 10.66 means the company can pay off $10.66 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 10.659. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.443. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ10.659TTM6.443+4.215
TTM6.443YOY5.707+0.737
TTM6.4435Y6.663-0.220
5Y6.66310Y7.647-0.984
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.6592.826+7.833
TTM6.4433.182+3.261
YOY5.7073.786+1.921
3Y6.0524.311+1.741
5Y6.6635.703+0.960
10Y7.6476.454+1.193
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Aligos Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Aligos assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Aligos to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.23 means that Aligos assets are financed with 22.7% credit (debt) and the remaining percentage (100% - 22.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 0.227. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.614. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.227TTM0.614-0.387
TTM0.614YOY0.410+0.204
TTM0.6145Y0.453+0.161
5Y0.45310Y0.543-0.090
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2270.329-0.102
TTM0.6140.349+0.265
YOY0.4100.331+0.079
3Y0.4330.340+0.093
5Y0.4530.349+0.104
10Y0.5430.379+0.164
4.5.4.2. Debt to Equity Ratio

Measures if Aligos is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Aligos to the Biotechnology industry mean.
  • A Debt to Equity ratio of 29.4% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Aligos Therapeutics Inc:

  • The MRQ is 0.294. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.419. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.294TTM0.419-0.125
TTM0.419YOY0.725-0.306
TTM0.4195Y0.392+0.027
5Y0.39210Y0.439-0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2940.379-0.085
TTM0.4190.437-0.018
YOY0.7250.414+0.311
3Y0.5090.450+0.059
5Y0.3920.464-0.072
10Y0.4390.515-0.076
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Aligos generates.

  • Above 15 is considered overpriced but always compare Aligos to the Biotechnology industry mean.
  • A PE ratio of 0.42 means the investor is paying $0.42 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Aligos Therapeutics Inc:

  • The EOD is 0.444. Based on the earnings, the company is cheap. +2
  • The MRQ is 0.417. Based on the earnings, the company is cheap. +2
  • The TTM is -0.239. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.444MRQ0.417+0.027
MRQ0.417TTM-0.239+0.656
TTM-0.239YOY-0.280+0.041
TTM-0.2395Y-1.680+1.441
5Y-1.68010Y-1.528-0.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.444-2.304+2.748
MRQ0.417-2.080+2.497
TTM-0.239-2.564+2.325
YOY-0.280-3.764+3.484
3Y-0.353-3.773+3.420
5Y-1.680-6.193+4.513
10Y-1.528-6.833+5.305
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Aligos Therapeutics Inc:

  • The EOD is -0.913. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.857. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -1.238. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.913MRQ-0.857-0.056
MRQ-0.857TTM-1.238+0.380
TTM-1.238YOY-0.330-0.908
TTM-1.2385Y-2.286+1.048
5Y-2.28610Y-2.078-0.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.913-3.132+2.219
MRQ-0.857-2.705+1.848
TTM-1.238-3.666+2.428
YOY-0.330-4.405+4.075
3Y-0.707-5.059+4.352
5Y-2.286-8.477+6.191
10Y-2.078-9.304+7.226
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Aligos is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.62 means the investor is paying $0.62 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Aligos Therapeutics Inc:

  • The EOD is 0.657. Based on the equity, the company is cheap. +2
  • The MRQ is 0.617. Based on the equity, the company is cheap. +2
  • The TTM is -1.727. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD0.657MRQ0.617+0.040
MRQ0.617TTM-1.727+2.344
TTM-1.727YOY0.343-2.071
TTM-1.7275Y0.763-2.491
5Y0.76310Y0.694+0.069
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.6571.953-1.296
MRQ0.6171.843-1.226
TTM-1.7272.112-3.839
YOY0.3432.441-2.098
3Y-0.3282.494-2.822
5Y0.7633.661-2.898
10Y0.6944.311-3.617
4.6.2. Total Gains per Share

2.4. Latest News of Aligos Therapeutics Inc

Does Aligos Therapeutics Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Aligos Therapeutics Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-06-13
14:00
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Read

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Aligos Therapeutics Inc.

4.8.1. Institutions holding Aligos Therapeutics Inc

Institutions are holding 65.641% of the shares of Aligos Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Adage Capital Partners Gp LLC7.60450.007146500014000043.0769
2025-03-31Deep Track Capital, LP7.26290.118644411020000081.9303
2025-03-31Alyeska Investment Group, L.P.6.73770.01354120004120000
2025-03-31Woodline Partners LP5.15770.01693153833153830
2025-03-31Heights Capital Management Inc3.94940.93542415002415000
2025-03-31Hudson Bay Capital Management LP3.94940.00582415002415000
2025-03-31Sio Capital Management, LLC2.95550.4441807201807200
2025-03-31Bank of America Corp2.52670.000115450315421854111.5789
2025-03-31TANG CAPITAL MANAGEMENT LLC2.3080.06441411311411310
2025-03-31Vanguard Group Inc2.301801407494398745.459
2025-03-31EcoR1 Capital, LLC1.44840.043388569-167004-65.3449
2025-03-31Baker Bros Advisors LP1.35830.00768305500
2025-03-31Hillhouse Capital Advisors, Ltd.1.24690.01787624700
2025-03-31Readystate Asset Management LP0.74250.012545400454000
2025-03-31Susquehanna International Group, LLP0.66420.000140612406120
2025-03-31Renaissance Technologies Corp0.64720.00053957628133245.8534
2025-03-31Trexquant Investment LP0.62560.003738254-30796-44.5996
2025-03-31Geode Capital Management, LLC0.45910280708172.9978
2025-03-31Wells Fargo & Co0.376602303012305.6422
2025-03-31Quest Partners LLC0.25770.014115760157600
Total 52.58011.70543215169+2004591+62.3%

4.9.2. Funds holding Aligos Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Vanguard Total Stock Mkt Idx Inv1.629809965800
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.64080.00023918200
2025-04-30Fidelity Extended Market Index0.22910.000214006-134-0.9477
2025-05-31Schwab US Small-Cap ETF™0.18690.00041143100
2025-03-31Extended Equity Market Fund K0.08710.00035328160.3012
2025-04-30Fidelity Total Market Index0.0710434300
2025-04-30Fidelity Series Total Market Index0.0593036251724.9812
2025-03-31NT Ext Equity Mkt Idx Fd - L0.0470.0003287300
2025-03-31Northern Trust Extended Eq Market Idx0.0470.0003287300
2025-04-30Spartan Extended Market Index Pool F0.04340.000226511345.3238
2025-03-31NT Ext Equity Mkt Idx Fd - NL0.03520.0003215000
2025-04-30Fidelity Nasdaq Composite Index0.03070.0001187900
2025-03-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02740.00031674-30-1.7606
2025-04-30Spartan Total Market Index Pool G0.02550155700
2025-05-31Avantis US Small Cap Equity ETF0.02330.0005142700
2025-05-31Schwab Total Stock Market Index0.02050125500
2025-04-30DFA US Targeted Value I0.01850.0001113100
2025-05-31Vanguard Balanced Index Inv0.0159097300
2025-04-30DFA US Sustainability Targeted Val Instl0.01570.001396000
2025-05-31Vanguard U.S. Eq Idx £ Acc0.0153093600
Total 3.26940.0045199912+158+0.1%

5.3. Insider Transactions

Insiders are holding 10.441% of the shares of Aligos Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-10-25Carole NuechterleinBUY31734419
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets150,699
Total Liabilities34,254
Total Stockholder Equity116,445
 As reported
Total Liabilities 34,254
Total Stockholder Equity+ 116,445
Total Assets = 150,699

Assets

Total Assets150,699
Total Current Assets143,205
Long-term Assets7,494
Total Current Assets
Cash And Cash Equivalents 73,763
Short-term Investments 64,098
Other Current Assets 5,344
Total Current Assets  (as reported)143,205
Total Current Assets  (calculated)143,205
+/-0
Long-term Assets
Property Plant Equipment 6,862
Long-term Assets Other 632
Long-term Assets  (as reported)7,494
Long-term Assets  (calculated)7,494
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities18,948
Long-term Liabilities15,306
Total Stockholder Equity116,445
Total Current Liabilities
Short-term Debt 3,487
Accounts payable 4,460
Other Current Liabilities 11,001
Total Current Liabilities  (as reported)18,948
Total Current Liabilities  (calculated)18,948
+/-0
Long-term Liabilities
Capital Lease Obligations 7,874
Long-term Liabilities Other 46
Long-term Liabilities  (as reported)15,306
Long-term Liabilities  (calculated)7,920
+/- 7,386
Total Stockholder Equity
Common Stock9
Retained Earnings -574,920
Accumulated Other Comprehensive Income 447
Other Stockholders Equity 690,909
Total Stockholder Equity (as reported)116,445
Total Stockholder Equity (calculated)116,445
+/-0
Other
Capital Stock9
Cash and Short Term Investments 137,861
Common Stock Shares Outstanding 8,710
Liabilities and Stockholders Equity 150,699
Net Debt -65,889
Net Invested Capital 116,445
Net Working Capital 124,257
Property Plant and Equipment Gross 18,838
Short Long Term Debt Total 7,874



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-06-302018-03-312017-12-31
> Total Assets 
0
0
0
0
0
0
0
146,520
0
148,676
92,183
265,302
234,540
211,876
263,068
235,369
210,470
182,523
164,069
146,693
121,738
106,130
85,852
153,903
127,902
108,811
88,426
70,094
150,699
150,69970,09488,426108,811127,902153,90385,852106,130121,738146,693164,069182,523210,470235,369263,068211,876234,540265,30292,183148,6760146,5200000000
   > Total Current Assets 
0
0
0
0
90,852
0
0
120,226
117,663
132,229
73,693
250,017
219,826
196,642
248,670
204,424
195,076
167,685
150,093
133,545
109,429
94,243
74,643
141,084
118,064
99,570
79,822
62,141
143,205
143,20562,14179,82299,570118,064141,08474,64394,243109,429133,545150,093167,685195,076204,424248,670196,642219,826250,01773,693132,229117,663120,2260090,8520000
       Cash And Cash Equivalents 
0
0
0
0
-90,852
0
0
69,565
-117,663
63,453
31,816
220,383
200,362
187,650
239,734
186,816
104,562
71,172
86,440
81,347
78,671
90,828
70,429
135,774
24,367
45,148
35,331
36,997
73,763
73,76336,99735,33145,14824,367135,77470,42990,82878,67181,34786,44071,172104,562186,816239,734187,650200,362220,38331,81663,453-117,66369,56500-90,8520000
       Short-term Investments 
0
0
0
0
181,704
0
0
48,098
235,326
65,444
38,248
23,130
13,053
3,003
2,451
3,918
78,660
88,172
55,864
44,480
24,845
10
0
0
88,588
49,458
39,591
19,942
64,098
64,09819,94239,59149,45888,588001024,84544,48055,86488,17278,6603,9182,4513,00313,05323,13038,24865,444235,32648,09800181,7040000
       Other Current Assets 
0
0
0
0
0
0
0
2,563
3,332
3,332
3,629
6,504
6,411
5,989
6,485
13,690
11,854
8,341
7,789
7,718
5,913
3,405
4,214
5,310
5,109
4,964
4,900
5,202
5,344
5,3445,2024,9004,9645,1095,3104,2143,4055,9137,7187,7898,34111,85413,6906,4855,9896,4116,5043,6293,3323,3322,5630000000
   > Long-term Assets 
0
0
0
0
0
0
0
26,294
0
16,447
18,490
15,285
14,714
15,234
14,398
30,945
15,394
14,838
13,976
13,148
12,309
11,887
11,209
12,819
9,838
9,241
8,604
9,710
7,494
7,4949,7108,6049,2419,83812,81911,20911,88712,30913,14813,97614,83815,39430,94514,39815,23414,71415,28518,49016,447026,2940000000
       Property Plant Equipment 
0
0
0
0
0
0
0
16,087
16,212
16,212
15,646
14,908
14,526
13,753
13,158
14,969
14,778
14,222
13,323
12,514
11,677
11,263
10,586
9,818
9,213
8,610
7,969
7,326
6,862
6,8627,3267,9698,6109,2139,81810,58611,26311,67712,51413,32314,22214,77814,96913,15813,75314,52614,90815,64616,21216,21216,0870000000
       Long Term Investments 
0
0
0
0
0
0
0
10,019
0
0
0
0
0
0
492
15,110
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000015,11049200000010,0190000000
       Other Assets 
0
0
0
0
0
0
0
0
235
235
2,844
7
188
1,481
13,906
866
616
616
653
634
0
624
0
0
0
0
0
-1,757
0
0-1,75700000624063465361661686613,9061,48118872,84423523500000000
> Total Liabilities 
0
0
0
0
0
0
0
211,411
0
26,718
228,851
45,263
39,320
42,992
46,057
50,638
57,584
45,542
42,056
42,793
36,988
36,495
31,031
61,823
68,106
41,582
38,330
99,067
34,254
34,25499,06738,33041,58268,10661,82331,03136,49536,98842,79342,05645,54257,58450,63846,05742,99239,32045,263228,85126,7180211,4110000000
   > Total Current Liabilities 
0
0
0
0
0
0
0
13,818
15,364
15,364
19,984
30,274
25,231
30,098
34,780
38,957
41,356
31,653
30,541
33,129
28,079
27,225
22,468
23,906
18,880
23,564
20,956
21,737
18,948
18,94821,73720,95623,56418,88023,90622,46827,22528,07933,12930,54131,65341,35638,95734,78030,09825,23130,27419,98415,36415,36413,8180000000
       Short-term Debt 
0
0
0
0
0
0
0
2,452
0
2,456
2,520
5,012
5,114
5,266
5,564
2,907
6,590
5,868
6,414
3,143
6,298
6,474
6,510
3,239
3,274
3,355
6,800
6,916
3,487
3,4876,9166,8003,3553,2743,2396,5106,4746,2983,1436,4145,8686,5902,9075,5645,2665,1145,0122,5202,45602,4520000000
       Accounts payable 
0
0
0
0
0
0
0
3,767
3,296
3,296
7,682
3,313
2,810
1,593
2,601
3,015
3,755
2,762
2,931
4,737
2,822
3,241
2,941
2,517
2,842
6,819
2,740
2,571
4,460
4,4602,5712,7406,8192,8422,5172,9413,2412,8224,7372,9312,7623,7553,0152,6011,5932,8103,3137,6823,2963,2963,7670000000
       Other Current Liabilities 
0
0
0
0
0
0
0
7,599
0
9,612
9,782
14,058
9,726
16,427
19,978
25,394
15,944
9,890
10,471
16,039
11,932
10,558
9,067
16,842
12,043
12,064
14,168
22,156
11,001
11,00122,15614,16812,06412,04316,8429,06710,55811,93216,03910,4719,89015,94425,39419,97816,4279,72614,0589,7829,61207,5990000000
   > Long-term Liabilities 
0
0
0
0
0
0
0
197,593
0
11,354
208,867
14,989
14,089
12,894
11,277
11,681
16,228
13,889
11,515
9,664
8,909
9,270
8,563
37,917
49,226
18,018
17,374
79,087
15,306
15,30679,08717,37418,01849,22637,9178,5639,2708,9099,66411,51513,88916,22811,68111,27712,89414,08914,989208,86711,3540197,5930000000
       Other Liabilities 
0
0
0
0
0
0
0
0
3,289
3,289
15,475
4,488
3,776
3,000
11,277
133
5,146
3,386
1,689
233
0
93
0
0
0
0
0
0
0
00000009302331,6893,3865,14613311,2773,0003,7764,48815,4753,2893,28900000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
2,610
0
0
737
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000737002,6100000000000
> Total Stockholder Equity
0
0
0
0
86,771
0
0
-64,891
117,188
121,958
-136,668
220,039
195,220
168,884
217,011
184,731
152,886
136,981
122,013
103,900
84,750
69,635
54,821
92,080
59,796
67,229
50,096
-28,973
116,445
116,445-28,97350,09667,22959,79692,08054,82169,63584,750103,900122,013136,981152,886184,731217,011168,884195,220220,039-136,668121,958117,188-64,8910086,7710000
   Common Stock
0
0
0
0
0
0
0
0
4
2
0
4
4
4
4
4
4
4
4
4
4
4
4
7
7
8
8
8
9
98887744444444444402400000000
   Retained Earnings Total Equity00000000-422,073-399,118000-303,072-265,358-232,232-202,414-174,74000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-115
0
150
32
-188
-227
-251
-250
452
204
50
159
401
499
497
497
545
476
494
577
451
447
44745157749447654549749749940115950204452-250-251-227-188321500-1150000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
394,963
397,857
401,363
482,615
487,347
0
0
0
502,613
506,320
0
0
0
0
0
0
0
0
00000000506,320502,613000487,347482,615401,363397,857394,96300000000000
   Treasury Stock00000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
-13,748
0
0
-180,658
-64,891
228,829
3,620
394,963
397,857
401,363
482,615
487,347
491,365
495,538
499,082
502,613
506,320
509,998
513,225
578,325
580,973
583,326
585,369
588,576
690,909
690,909588,576585,369583,326580,973578,325513,225509,998506,320502,613499,082495,538491,365487,347482,615401,363397,857394,9633,620228,829-64,891-180,65800-13,7480000



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue3,945
Cost of Revenue-2,622
Gross Profit1,3231,323
 
Operating Income (+$)
Gross Profit1,323
Operating Expense-93,099
Operating Income-89,154-91,776
 
Operating Expense (+$)
Research Development70,269
Selling General Administrative22,830
Selling And Marketing Expenses0
Operating Expense93,09993,099
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-4,406
Net Interest Income4,406
 
Pretax Income (+$)
Operating Income-89,154
Net Interest Income4,406
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-130,880-47,428
EBIT - interestExpense = 0
-130,880
-131,211
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-130,880
Earnings Before Interest and Taxes (EBITDA)-89,154
 
After tax Income (+$)
Income Before Tax-130,880
Tax Provision-331
Net Income From Continuing Ops-131,211-131,211
Net Income-131,211
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses93,099
Total Other Income/Expenses Net-41,726-4,406
 

Technical Analysis of Aligos
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Aligos. The general trend of Aligos is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Aligos's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Aligos Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Aligos Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 9.51 < 12.19 < 28.10.

The bearish price targets are: 8.655 > 6.8242 > 6.45.

Know someone who trades $ALGS? Share this with them.👇

Aligos Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Aligos Therapeutics Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Aligos Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartAligos Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Aligos Therapeutics Inc. The current adx is .

Aligos Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Relative Strength Index (RSI) ChartAligos Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Stochastic Oscillator ChartAligos Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Commodity Channel Index (CCI) ChartAligos Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartAligos Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Williams %R ChartAligos Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Average True Range (ATR) ChartAligos Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily On-Balance Volume (OBV) ChartAligos Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Aligos Therapeutics Inc.

Aligos Therapeutics Inc Daily Money Flow Index (MFI) ChartAligos Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Aligos Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-21BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-07MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-10ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-19RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-23MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-13STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-24SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Aligos Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Aligos Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose8.640
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Aligos with someone you think should read this too:
  • Are you bullish or bearish on Aligos? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Aligos? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Aligos Therapeutics Inc

I send you an email if I find something interesting about Aligos Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Aligos Therapeutics Inc.

Receive notifications about Aligos Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.